2nd Department of Internal Medicine, Sismanogleion Athens Hospital, Athens 15126, Greece.
J Crit Care. 2011 Jun;26(3):331.e1-7. doi: 10.1016/j.jcrc.2010.07.012. Epub 2010 Sep 24.
The objective of this study is to define if early changes of procalcitonin (PCT) may inform about prognosis and appropriateness of administered therapy in sepsis.
A prospective multicenter observational study was conducted in 289 patients. Blood samples were drawn on day 1, that is, within less than 24 hours from advent of signs of sepsis, and on days 3, 7, and 10. Procalcitonin was estimated in serum by the ultrasensitive Kryptor assay (BRAHMS GmbH, Hennigsdorf, Germany). Patients were divided into the following 2 groups according to the type of change of PCT: group 1, where PCT on day 3 was decreased by more than 30% or was below 0.25 ng/mL, and group 2, where PCT on day 3 was either increased above 0.25 ng/mL or decreased less than 30%.
Death occurred in 12.3% of patients of group 1 and in 29.9% of those of group 2 (P < .0001). Odds ratio for death of patients of group 1 was 0.328. Odds ratio for the administration of inappropriate antimicrobials of patients of group 2 was 2.519 (P = .003).
Changes of serum PCT within the first 48 hours reflect the benefit or not of the administered antimicrobial therapy. Serial PCT measurements should be used in clinical practice to guide administration of appropriate antimicrobials.
本研究旨在确定降钙素原(PCT)的早期变化是否可以提示脓毒症患者的预后和所给予治疗的适宜性。
进行了一项前瞻性多中心观察性研究,共纳入 289 例患者。在第 1 天(即从出现脓毒症迹象不到 24 小时内)及第 3、7 和 10 天抽取血样。采用 BRAHMS GmbH(德国亨尼希多夫)的 ultrasensitive Kryptor 检测法检测血清中的降钙素原。根据 PCT 第 3 天的变化,将患者分为以下 2 组:组 1,PCT 第 3 天降低超过 30%或低于 0.25ng/mL;组 2,PCT 第 3 天升高超过 0.25ng/mL或降低不足 30%。
第 1 组患者中有 12.3%死亡,第 2 组患者中有 29.9%死亡(P<.0001)。组 1 患者死亡的优势比为 0.328。组 2 患者接受不适当抗菌药物治疗的优势比为 2.519(P=0.003)。
最初 48 小时内血清 PCT 的变化反映了所给予抗菌治疗的获益与否。应在临床实践中使用连续 PCT 测量来指导适当抗菌药物的应用。